azd4360

Gastric Cancer

AstraZenecaPhase 1/2Active

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 65/ 100

Competitive context

282 Active assets in the Gastric Cancer cohort.

Asset / Sponsor	Phase	Rating
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 4	BBB
FLUOROURACILUM I-Mab Biopharma US Limited	Phase 4	BB
Eloxatin Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
Pembrolizumab Eikon Therapeutics	Phase 3	BB
Epirubicin Rondo Therapeutics	Phase 3	BB

View all 50 →

Same molecule, other indications

azd4360 is also rated in:

gastroesophageal junction adenocarcinomaDormant

CCC

Indicative ·

48 / 100

biliary tract cancerDormant

CC

Indicative ·

43 / 100

pancreatic ductal adenocarcinomaDormant

CC

Indicative ·

41 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.